Trupanion (TRUP) 10-Q 3 May 24 2024 Q1 Quarterly report Financial data

Cover Page Document

Cover Page Document - shares	3 Months Ended
	Mar. 31, 2024	Apr. 26, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-36537
Entity Registrant Name	TRUPANION, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-0480694
Entity Address, Address Line One	6100 4th Avenue S, Suite 200
Entity Address, City or Town	Seattle,
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98108
City Area Code	(855)
Local Phone Number	727 - 9079
Title of 12(b) Security	Common stock, $0.00001 par value per share
Trading Symbol	TRUP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,020,485
Entity Central Index Key	0001371285
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Statement of Opera

Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 306,121	$ 256,329
Claims Expense	233,569	194,137
Other Cost of Services Sold	36,325	35,846
Cost of Revenue	269,894	229,983
Technology and Development Expense	6,960	4,900
General and Administrative Expense	14,673	21,017
Selling and Marketing Expense	16,843	21,642
Depreciation, Depletion and Amortization	3,785	3,202
Operating Expenses	42,261	50,761
Income (Loss) from Equity Method Investments	(103)	(71)
Operating Income (Loss), Total	(6,137)	(24,486)
Interest Expense	3,596	2,387
Other Nonoperating Income (Expense)	(2,843)	(1,902)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(6,890)	(24,971)
Income Tax Expense (Benefit)	(38)	(191)
Net Income (Loss) Available to Common Stockholders, Basic, Total	$ (6,852)	$ (24,780)
Earnings Per Share, Basic and Diluted [Abstract]
Earnings Per Share, Basic	$ (0.16)	$ (0.60)
Earnings Per Share, Diluted	$ (0.16)	$ (0.60)
Weighted Average Number of Shares Outstanding, Basic	41,917,094	41,107,889
Weighted Average Number of Shares Outstanding, Diluted	41,917,094	41,107,889

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income Statement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic, Total	$ (6,852)	$ (24,780)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(1,332)	1,555
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(652)	491
Other Comprehensive Income (Loss), Net of Tax, Total	(1,984)	2,046
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (8,836)	$ (22,734)

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 146,455	$ 147,501
Short-term Investments	128,734	129,667
Accounts and Other Receivables, Net, Current	278,492	267,899
Prepaid Expense and Other Assets	17,084	17,022
Assets, Current, Total	570,765	562,089
Restricted Cash and Cash Equivalents	23,106	22,963
Marketable Securities, Noncurrent	13,007	12,866
Property, Plant and Equipment, Net	104,365	103,650
Intangible Assets, Net (Excluding Goodwill)	17,221	18,745
Other Assets, Noncurrent	18,013	18,922
Goodwill	42,983	43,713
Assets, Total	789,460	782,948
Liabilities and Equity [Abstract]
Accounts Payable, Current	8,348	10,505
Accrued Liabilities, Current	30,473	34,052
Liability for Claims and Claims Adjustment Expense	62,275	63,238
Deferred Revenue	249,135	235,329
Long-term Debt, Current Maturities	1,350	1,350
Liabilities, Current, Total	351,581	344,474
Long-term Debt, Excluding Current Maturities	127,482	127,580
Deferred Income Tax Liabilities, Net	2,399	2,685
Other Liabilities, Noncurrent	4,627	4,487
Liabilities, Total	486,089	479,226
Common Stock, Value, Outstanding	0	0
Preferred Stock, Value, Outstanding	0	0
Additional Paid in Capital	544,593	536,108
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,581)	403
Retained Earnings (Accumulated Deficit)	(223,107)	(216,255)
Treasury Stock, Value	(16,534)	(16,534)
Stockholders' Equity Attributable to Parent	303,371	303,722
Liabilities and Equity	$ 789,460	$ 782,948

Consolidated Balance Sheet Cond

Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for Doubtful Accounts, Premiums and Other Receivables	$ 1,093,000	$ 1,085,000
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	43,032,805	42,887,052
Common Stock, Shares, Outstanding	42,004,619	41,858,866
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Common, Shares	1,028,186	1,028,186

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2022		41,013,158
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2022	$ 305,297	$ 0	$ 499,694	$ (171,562)	$ (6,301)	$ (16,534)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		314,544
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	(713)		(713)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	12,959		12,959
Other Comprehensive Income (Loss), Net of Tax	2,046				2,046
Net Income (Loss) Available to Common Stockholders, Basic	(24,780)			(24,780)
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2023		41,327,702
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2023	$ 294,809	$ 0	511,940	(196,342)	(4,255)	(16,534)
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2023	41,858,866	41,858,866
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2023	$ 303,722	$ 0	536,108	(216,255)	403	(16,534)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		145,753
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	127		127
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,358		8,358
Other Comprehensive Income (Loss), Net of Tax	(1,984)				(1,984)
Net Income (Loss) Available to Common Stockholders, Basic	$ (6,852)			(6,852)
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2024	42,004,619	42,004,619
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2024	$ 303,371	$ 0	$ 544,593	$ (223,107)	$ (1,581)	$ (16,534)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Cash Flows [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ (6,852,000)	$ (24,780,000)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	3,785,000	3,202,000
Share-based Payment Arrangement, Noncash Expense	8,152,000	12,331,000
Other Operating Income (Expense), Net	(202,000)	(397,000)
Increase (Decrease) in Operating Assets [Abstract]
Increase (Decrease) in Accounts Receivable	(10,718,000)	(15,847,000)
Increase (Decrease) in Prepaid Expense and Other Assets	287,000	(3,765,000)
Increase (Decrease) in Accounts Payable and Accrued Liabilities	(5,131,000)	(5,148,000)
Increase (Decrease) in Claims Reserve and Loss Adjustment	(885,000)	4,606,000
Increase (Decrease) in Unearned Premiums	13,998,000	22,936,000
Net Cash Provided by (Used in) Operating Activities	2,434,000	(6,862,000)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Payments to Acquire Held-to-maturity Securities	(19,193,000)	(34,795,000)
Maturities of Investment Securities	19,005,000	73,793,000
Payments to Acquire Property, Plant, and Equipment	(3,065,000)	(5,184,000)
Payments for (Proceeds from) Other Investing Activities	516,000	100,000
Net Cash Provided by (Used in) Investing Activities	(2,737,000)	33,914,000
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from Issuance of Debt	0	35,130,000
Repayments of Debt	(338,000)	(607,000)
Proceeds from Stock Options Exercised	372,000	140,000
Payment, Tax Withholding, Share-based Payment Arrangement	(245,000)	(853,000)
Proceeds from (Payments for) Other Financing Activities	(75,000)	0
Net Cash Provided by (Used in) Financing Activities	(286,000)	33,810,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(313,000)	260,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(902,000)	61,122,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	170,464,000	84,637,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	169,562,000	145,759,000
Supplemental Cash Flow Information [Abstract]
Capital Expenditures Incurred but Not yet Paid	$ 694,000	$ 1,243,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies (Notes)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Nature of Operations and Significant Accounting Policies Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics. The financial data as of December 31, 2023 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024 (the 2023 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2023 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2023 10-K for additional discussion of these estimates and assumptions.

Earnings Per Share (Notes)

Earnings Per Share (Notes)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Net Loss per Share Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, unvested restricted stock awards and restricted stock units. The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended March 31, 2024 2023 Stock options 386,312 615,913 Restricted stock awards and restricted stock units 1,262,794 813,718

Investment Securities (Notes)

Investment Securities (Notes)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Investment [Text Block]	Investments Available-for sale securities are classified as short-term versus long-term investments based on whether they represent the investment of funds available for current operations. All available-for-sale securities are considered short-term in nature, with the exception of certain long-term investments that are being held for statutory requirements. Held-to-maturity securities are classified as short-term versus long-term investments based on the effective maturity dates. The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2024 and December 31, 2023 (in thousands): Amortized Gross Gross Fair As of March 31, 2024 Long-term investments: Available-for-sale investments Foreign deposits $ 12,009 $ — $ — $ 12,009 $ 12,009 $ — $ — $ 12,009 Held-to-maturity investments U.S. treasury securities $ 998 $ — $ — $ 998 $ 998 $ — $ — $ 998 Short-term investments: Available-for-sale investments U.S. treasury securities $ 43,416 $ 77 $ (208) $ 43,285 Mortgage-backed securities and collateralized mortgage obligations 10,905 29 (97) 10,837 Other asset-backed securities 13,571 41 (61) 13,551 Corporate bonds 36,099 177 (132) 36,144 $ 103,991 $ 324 $ (498) $ 103,817 Held-to-maturity investments U.S. treasury securities $ 12,929 $ 2 $ (8) $ 12,923 Certificates of deposit 11,988 — — 11,988 $ 24,917 $ 2 $ (8) $ 24,911 Amortized Gross Gross Fair As of December 31, 2023 Long-term investments: Available-for-sale investments Foreign deposits $ 11,869 $ — $ — $ 11,869 $ 11,869 $ — $ — $ 11,869 Held-to-maturity investments U.S. treasury securities $ 997 $ 8 $ — $ 1,005 $ 997 $ 8 $ — $ 1,005 Short-term investments: Available-for-sale investments U.S. treasury securities $ 44,425 $ 326 $ (64) $ 44,687 Mortgage-backed securities and collateralized mortgage obligations 10,460 69 (75) 10,454 Other asset-backed securities 12,422 67 (53) 12,436 Corporate bonds 36,404 332 (123) 36,613 $ 103,711 $ 794 $ (315) $ 104,190 Held-to-maturity investments U.S. treasury securities $ 13,179 $ 21 $ (15) $ 13,185 Certificates of deposit 12,298 — — 12,298 $ 25,477 $ 21 $ (15) $ 25,483 Maturities of investments classified as available-for-sale and held-to-maturity were as follows (in thousands): As of March 31, 2024 Amortized Fair Available-for-sale: Due under one year $ 4,084 $ 4,050 Due after one year through five years 87,440 87,388 $ 91,524 $ 91,438 Available-for-sale collateralized: Mortgage-backed securities and collateralized mortgage obligations $ 10,905 $ 10,837 Other asset-backed securities 13,571 13,551 $ 24,476 $ 24,388 Held-to-maturity: Due under one year $ 24,917 $ 24,911 Due after one year through five years 998 998 $ 25,915 $ 25,909 The Company does not expect any credit losses from its held-to-maturity investments, considering the composition of the investment portfolio and the credit loss history of these investments. For available-for-sale investments, the Company determined that there were unrealized losses of $0.5 million and $0.3 million as of March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024, $24.9 million in available-for-sale investments have been in a loss position for more than twelve months, with total unrealized losses of $0.3 million. As of March 31, 2024, $39.4 million available-for-sale investments have been in a loss position for less than twelve months, with total unrealized losses of $0.2 million. As of December 31, 2023, $18.9 million in available-for-sale investments have been in a loss position for more than twelve months, with total unrealized losses of $0.2 million. As of December 31, 2023, $25.9 million available-for-sale investments have been in a loss position for less than twelve months, with total unrealized losses of $0.1 million. These losses relate to interest rate changes. The Company does not expect any credit losses from its available-for-sale investments, considering the composition of the investment portfolio and the credit rating of these investments. For those securities, the Company determined it is not likely to, and does not intend to, sell prior to a potential recovery.

Other Investments (Notes)

Other Investments (Notes)	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Investments and Other Noncurrent Assets [Text Block]	Other Investments The Company has invested $7.0 million in the preferred stock of a variable interest entity, Baystride, Inc. ("Baystride"), a U.S.-based privately held corporation operating in the pet food industry. The Company does not have power over the activities that most significantly impact the economic performance of the entity and is, therefore, not the primary beneficiary. The Company has the option to purchase all of the outstanding common stock issued by the entity in August 2027 at an amount approximating its expected fair value. The preferred stock investment in the entity is redeemable, and therefore, is accounted for as an available-for-sale debt security, and measured at fair value at each balance sheet date — see Note 5. Additionally, the Company has extended a $7.0 million revolving line of credit to Baystride to fund its inventory purchases, which will increase annually by $2.0 million until the note’s maturity in 2027. Borrowing amounts are subject to limitations based on Baystride’s forecasted revenues and inventory balances. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit, including accrued interest, was $3.3 million and $4.0 million as of March 31, 2024 and December 31, 2023, respectively. The Company has also entered into a series of agreements to provide ancillary services to, and receive reimbursement from, Baystride at cost. The Company provided $0.1 million and $0.2 million of these services for the three months ended March 31, 2024 and 2023, respectively. Allowance for Credit Loss The Company regularly evaluates its investments for expected credit losses. The Company considers past events, current conditions, and reasonable and supportable forecasts in estimating an allowance for credit losses. Additionally, the Company considers the ultimate collection of cash flows from its investments and whether the Company has the intent to sell, or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. Such evaluations are revised as conditions change and new information becomes available. Based on these considerations, the Company has established an allowance for credit losses related to its preferred stock investment. The following table presents a rollforward of the allowance for credit losses for this investment. Balance as of January 1, 2023 $ — (Addition to) allowance for credit losses — Balance as of March 31, 2023 $ — Balance as of January 1, 2024 $ (1,674) (Addition to) allowance for credit losses — Balance as of March 31, 2024 $ (1,674)

Fair Value (Notes)

Fair Value (Notes)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Fair Value Disclosures - Investments The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of March 31, 2024 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 81,906 $ 81,906 $ — $ — Fixed maturities: Mortgage-backed securities and collateralized mortgage obligations 10,837 — 10,837 — Other asset-backed securities 13,551 — 13,551 — Corporate bonds 36,144 — 36,144 — Foreign deposits 12,009 12,009 — — U.S. Treasury securities 43,285 — 43,285 — Preferred stock investment 5,326 — — 5,326 Total $ 203,058 $ 93,915 $ 103,817 $ 5,326 As of December 31, 2023 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 67,360 $ 67,360 $ — $ — Fixed maturities: Mortgage-backed securities and collateralized mortgage obligations 10,454 — 10,454 — Other asset-backed securities 12,436 — 12,436 — Corporate bonds 36,613 — 36,613 — Foreign deposits 11,869 11,869 — — U.S. Treasury securities 44,687 — 44,687 — Preferred stock investment 5,326 — — 5,326 Total $ 188,745 $ 79,229 $ 104,190 $ 5,326 The Company measures the fair value of money market funds and foreign deposits, classified as Level 1, based on quoted prices in active markets for identical assets. The Company's fixed maturity investments classified as either Level 1 or Level 2 in the above tables are priced exclusively by external sources, including pricing vendors, dealers/market makers, and exchange-quoted prices. The fair value of the Company's fixed maturity investments classified as Level 2 is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Held-to-maturity investments are carried at amortized cost and the fair value and changes in unrealized gains (losses) are disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as available-for-sale securities and are considered either a Level 1 or Level 2 measurement. The Company's preferred stock investment (see Note 4) is accounted for as an available-for-sale debt security, and measured at fair value at each balance sheet date. The estimated fair value of the preferred stock investment is a Level 3 measurement, and is based on certain unobservable inputs such as the value of the underlying enterprise, volatility, time to liquidity, and market interest rates. An increase or decrease in any of these unobservable inputs would result in a change in the fair value measurement. The estimated fair value was $5.3 million as of March 31, 2024, unchanged from December 31, 2023, and is recorded in other long-term assets on the Company's consolidated balance sheet. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers between levels for the three months ended March 31, 2024 and the year ended December 31, 2023. The following table presents the change in fair value of the Company’s investment carried at fair value and classified as Level 3 as of March 31, 2024 and 2023 (in thousands): Preferred Stock Investment Balance as of January 1, 2024 $ 5,326 Changes in fair value included in earnings — Balance as of March 31, 2024 $ 5,326 Preferred Stock Investment Balance as of January 1, 2023 $ 4,115 Changes in fair value included in earnings — Balance as of March 31, 2023 $ 4,115 Fair Value Disclosures - Other Assets and Liabilities The Company's other long-term assets balance also included notes receivable of $6.1 million and $6.8 million as of March 31, 2024 and December 31, 2023, respectively, recorded at their estimated collectible amount. The Company estimates that the carrying value of the notes receivable approximates the fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2024.

Commitment and Contingencies (N

Commitment and Contingencies (Notes)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Legal Proceedings From time to time the Company is or may become subject to various legal proceedings arising in the ordinary course of business, including proceedings against members, other entities or regulatory bodies. Estimated liabilities are recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments.

Claims Reserve (Notes)

Claims Reserve (Notes)	3 Months Ended
	Mar. 31, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Disclosure [Text Block]	Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that have not been processed or received but that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. Reserve for veterinary invoices Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Three Months Ended March 31, Subscription 2024 2023 Reserve at beginning of year $ 31,549 $ 21,543 Veterinary invoices during the period related to: Current year 151,793 127,343 Prior years 563 1,645 Total veterinary invoice expense 152,356 128,988 Amounts paid during the period related to: Current year 128,639 108,483 Prior years 24,386 17,529 Total paid 153,025 126,012 Non-cash expenses 864 877 Reserve at end of period $ 30,016 $ 23,642 The Company had unfavorable development on veterinary invoice reserves for the subscription business segment of $0.6 million for the three months ended March 31, 2024, and unfavorable development on veterinary invoice reserves of $1.6 million for the three months ended March 31, 2023, both of which were the result of ongoing analysis of recent payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Three Months Ended March 31, Other Business 2024 2023 Reserve at beginning of year $ 31,690 $ 22,191 Veterinary invoices during the period related to: Current year 80,876 63,948 Prior years 337 1,200 Total veterinary invoice expense 81,213 65,148 Amounts paid during the period related to: Current year 55,059 44,564 Prior years 25,585 18,122 Total paid 80,644 62,686 Non-cash expenses — — Reserve at end of period $ 32,259 $ 24,653 The Company had unfavorable development on veterinary invoice reserves for the other business segment of $0.3 million for the three months ended March 31, 2024, and unfavorable development on veterinary invoice reserves of $1.2 million for the three months ended March 31, 2023, both of which were the result of ongoing analysis of recent payment trends. Reserve for veterinary invoices, by year of occurrence In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence. Subscription As of March 31, 2024 Year of Occurrence 2022 and prior $ 698 2023 7,027 2024 22,291 $ 30,016 Other Business As of March 31, 2024 Year of Occurrence 2022 and prior $ 576 2023 5,867 2024 25,816 $ 32,259

Debt (Notes)

Debt (Notes)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Debt On March 25, 2022, the Company entered into a credit agreement with Piper Sandler Finance, LLC, acting as the administrative agent, that provides the Company with $150.0 million in credit (the Credit Facility) consisting of: (a) an initial term loan in an aggregate principal amount of $60.0 million (Initial Term Loan), which was funded at closing; (b) commitments for delayed draw term loans in an aggregate principal amount not in excess of $75.0 million (Delayed Draw Term Loans, and together with the Initial Term Loan, the Term Loans), which may be drawn from time to time until September 25, 2023. On December 29, 2022, February 17, 2023, and September 21, 2023, the Company borrowed Delayed Draw Term loans of $15.0 million, $35.0 million, and $25.0 million, respectively; and (c) commitments for revolving loans in an aggregate principal amount at any time outstanding not in excess of $15.0 million (Revolving Loans), which may be drawn at any time prior to March 25, 2027. The Credit Facility bears interest at a floating base rate plus an applicable margin. The stated interest rate as of March 31, 2024 was approximately 10.46% for the original $60.0 million term loan and for the aggregate $75.0 million term loans. The Company incurred total debt issuance cost of approximately $5.9 million, which is reported in the consolidated balance sheet as a direct reduction from the carrying amount of the Credit Facility, and is amortized as interest expense over the term of five years. The Credit Facility is secured by substantially all assets of the Company and its subsidiaries. Proceeds from the Credit Facility may be used for permitted acquisitions and investments, working capital and other general corporate purposes. The Credit Agreement contains financial and other covenants . As of March 31, 2024, the Company was in compliance with all financial and other covenants . To the extent not previously paid, the Initial Term Loan is due and payable on March 25, 2027, the Delayed Draw Term Loans are due and payable on the earlier of the five-year anniversary of their initial funding or March 25, 2028, and Revolving Loans are due and payable on March 25, 2027. The Company must repay 0.25% of any then-outstanding Term Loans, together with accrued and unpaid interest, on a quarterly basis. Future principal payments on outstanding borrowings as of March 31, 2024 are as follows (in thousands): Year Ending December 31, March 31, 2024 2024 $ 1,012 2025 1,350 2026 1,350 2027 72,113 2028 57,125 Thereafter — Total $ 132,950

Stock-based Compensation (Notes

Stock-based Compensation (Notes)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Stock-Based Compensation Stock-based compensation expense includes stock options and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in each category of the consolidated statements of operations was as follows (in thousands): Three Months Ended March 31, 2024 2023 Veterinary invoice expense $ 924 $ 853 Other cost of revenue 466 465 Technology and development 1,254 708 General and administrative 3,449 8,219 New pet acquisition expense 2,059 2,086 Total expensed stock-based compensation 8,152 12,331 Capitalized stock-based compensation 206 628 Total stock-based compensation $ 8,358 $ 12,959 Restricted Stock Awards and Restricted Stock Units A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2023 714,382 $ 66.64 Granted 761,553 26.92 Vested (200,289) 69.84 Forfeited (12,852) 56.94 Unvested shares as of March 31, 2024 1,262,794 $ 42.28 As of March 31, 2024, the Company had 1,262,794 unvested restricted stock units. Stock-based compensation expenses of $56.1 million related to unvested restricted stock units are expected to be recognized over a weighted average period of approximately 2.4 years. In March 2023, two executives terminated employment with the Company and one executive signed a separation agreement effective June 1, 2023. In conjunction with these departures, the Company accelerated the vesting of certain RSUs as of the termination date and extended the purchase date of certain vested options from 90 to 365 days. These award modifications resulted in the recognition of $4.8 million share-based compensation expense during the quarter ended March 31, 2023. Stock Options A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 408,970 $ 14.09 $ 6,715 Granted — — — Exercised (22,658) 16.41 338 Forfeited — — Outstanding as of March 31, 2024 386,312 13.95 5,275 Exercisable as of March 31, 2024 386,312 $ 13.95 $ 5,275 As of March 31, 2024, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 2.4 years.

Stockholders' Equity (Notes)

Stockholders' Equity (Notes)	3 Months Ended
	Mar. 31, 2024
Equity, Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders' Equity Common Stock and Preferred Stock As of March 31, 2024, the Company had 100,000,000 shares of common stock authorized and 42,004,619 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At March 31, 2024, the Company had 10,000,000 shares of undesignated preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company (the Board), whenever funds are legally available. These rights are subordinate to the dividend rights of holders of any senior classes of stock outstanding at the time. The Company does not intend to declare or pay any cash dividends in the foreseeable future. Share Repurchase Program In April 2021, the Board approved a share repurchase program, pursuant to which the Company may, between May 2021 and May 2026, repurchase outstanding shares of the Company's common stock. The Company repurchased no shares during the three months ended March 31, 2024 and 2023, respectively.

Comprehensive Income (Loss) (No

Comprehensive Income (Loss) (Notes)	3 Months Ended
	Mar. 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Accumulated Comprehensive Income (Loss) A summary of the components of accumulated other comprehensive income (loss) is as follows (in thousands): For the three months ended March 31, 2024 Foreign Currency Translation Net Unrealized Gain (Loss) on Available-for-Sale Securities Total Balance as of January 1, 2024 $ (76) $ 479 $ 403 Other comprehensive income (loss) (1,332) (652) (1,984) Balance as of March 31, 2024 $ (1,408) $ (173) $ (1,581) For the three months ended March 31, 2023 Foreign Currency Translation Net Unrealized Gain (Loss) on Available-for-Sale Securities Total Balance as of January 1, 2023 $ (2,788) $ (3,513) $ (6,301) Other comprehensive income (loss) 1,555 491 2,046 Balance as of March 31, 2023 $ (1,233) $ (3,022) $ (4,255)

Segments (Notes)

Segments (Notes)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Segments The Company has two aggregated reporting segments: subscription business and other business. The subscription business segment consists of products that have been created to meet the needs of their distribution channels and have similar target margin profiles. This segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products. The other business segment generates revenue primarily by underwriting policies on behalf of third parties. The Company does not undertake marketing efforts for these policies and has a business-to-business relationship with these third-parties. The other business segment also includes other products and insurance software solutions that have a different margin profile from the Company’s subscription business segment. The chief operating decision maker reviews revenue and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, and new pet acquisition expenses are generally directly attributed to each segment. Other operating expenses, such as technology and development expense, general and administrative expense, and depreciation and amortization, are generally allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. Operating income (loss) of the Company’s segments were as follows (in thousands): Three Months Ended March 31, 2024 2023 Subscription business: Revenue $ 201,134 $ 165,210 Veterinary invoice expense 152,356 128,988 Other cost of revenue 19,776 17,103 Technology and development 4,573 3,158 General and administrative 9,641 11,073 New pet acquisition expense 16,826 21,591 Depreciation and amortization 2,487 2,064 Subscription business operating loss (4,525) (18,767) Other business: Revenue 104,987 91,119 Veterinary invoice expense 81,213 65,149 Other cost of revenue 16,549 18,743 Technology and development 2,387 1,742 General and administrative 5,032 9,944 New pet acquisition expense 17 51 Depreciation and amortization 1,298 1,138 Other business operating loss (1,509) (5,648) Loss from investment in joint venture (103) (71) Operating loss (6,137) (24,486) Interest expense 3,596 2,387 Other income, net (2,843) (1,902) Loss before income taxes $ (6,890) $ (24,971) The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended March 31, 2024 2023 United States $ 255,974 $ 216,925 Canada and other 50,147 39,404 Total revenue $ 306,121 $ 256,329 Substantially all of the Company’s long-lived assets were located in the United States as of March 31, 2024 and December 31, 2023.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Rule 10b5-1 Plan During the three months ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted or terminated, including by modification, a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted	true
Rule 10b5-1 Arrangement Terminated	true
Non-Rule 10b5-1 Arrangement Terminated	true

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics.
Basis of Accounting, Policy [Policy Text Block]	The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2023 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2023 10-K for additional discussion of these estimates and assumptions.

Other Investments (Policies)

Other Investments (Policies)	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Additionally, the Company has extended a $7.0 million revolving line of credit to Baystride to fund its inventory purchases, which will increase annually by $2.0 million until the note’s maturity in 2027. Borrowing amounts are subject to limitations based on Baystride’s forecasted revenues and inventory balances. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. The outstanding loan balance under the line of credit, including accrued interest, was $3.3 million and $4.0 million as of March 31, 2024 and December 31, 2023, respectively. The Company has also entered into a series of agreements to provide ancillary services to, and receive reimbursement from, Baystride at cost. The Company provided $0.1 million and $0.2 million of these services for the three months ended March 31, 2024 and 2023, respectively.

Fair Value (Policies)

Fair Value (Policies)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement, Policy [Policy Text Block]	The Company's other long-term assets balance also included notes receivable of $6.1 million and $6.8 million as of March 31, 2024 and December 31, 2023, respectively, recorded at their estimated collectible amount. The Company estimates that the carrying value of the notes receivable approximates the fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at March 31, 2024.

Claims Reserve (Policies)

Claims Reserve (Policies)	3 Months Ended
	Mar. 31, 2024
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Liability Reserve Estimate, Policy [Policy Text Block]	The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that have not been processed or received but that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense.

Segments (Policies)

Segments (Policies)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Reporting, Policy [Policy Text Block]	The Company has two aggregated reporting segments: subscription business and other business. The subscription business segment consists of products that have been created to meet the needs of their distribution channels and have similar target margin profiles. This segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products. The other business segment generates revenue primarily by underwriting policies on behalf of third parties. The Company does not undertake marketing efforts for these policies and has a business-to-business relationship with these third-parties. The other business segment also includes other products and insurance software solutions that have a different margin profile from the Company’s subscription business segment. The chief operating decision maker reviews revenue and operating income (loss) to evaluate segment performance. Revenue, veterinary invoice expense, other cost of revenue, and new pet acquisition expenses are generally directly attributed to each segment. Other operating expenses, such as technology and development expense, general and administrative expense, and depreciation and amortization, are generally allocated proportionately based on revenue in each segment. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended March 31, 2024 2023 Stock options 386,312 615,913 Restricted stock awards and restricted stock units 1,262,794 813,718

Investments, Debt and Equity Se

Investments, Debt and Equity Securities (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Unrealized Gain (Loss) on Investments [Table Text Block]	The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of March 31, 2024 and December 31, 2023 (in thousands): Amortized Gross Gross Fair As of March 31, 2024 Long-term investments: Available-for-sale investments Foreign deposits $ 12,009 $ — $ — $ 12,009 $ 12,009 $ — $ — $ 12,009 Held-to-maturity investments U.S. treasury securities $ 998 $ — $ — $ 998 $ 998 $ — $ — $ 998 Short-term investments: Available-for-sale investments U.S. treasury securities $ 43,416 $ 77 $ (208) $ 43,285 Mortgage-backed securities and collateralized mortgage obligations 10,905 29 (97) 10,837 Other asset-backed securities 13,571 41 (61) 13,551 Corporate bonds 36,099 177 (132) 36,144 $ 103,991 $ 324 $ (498) $ 103,817 Held-to-maturity investments U.S. treasury securities $ 12,929 $ 2 $ (8) $ 12,923 Certificates of deposit 11,988 — — 11,988 $ 24,917 $ 2 $ (8) $ 24,911 Amortized Gross Gross Fair As of December 31, 2023 Long-term investments: Available-for-sale investments Foreign deposits $ 11,869 $ — $ — $ 11,869 $ 11,869 $ — $ — $ 11,869 Held-to-maturity investments U.S. treasury securities $ 997 $ 8 $ — $ 1,005 $ 997 $ 8 $ — $ 1,005 Short-term investments: Available-for-sale investments U.S. treasury securities $ 44,425 $ 326 $ (64) $ 44,687 Mortgage-backed securities and collateralized mortgage obligations 10,460 69 (75) 10,454 Other asset-backed securities 12,422 67 (53) 12,436 Corporate bonds 36,404 332 (123) 36,613 $ 103,711 $ 794 $ (315) $ 104,190 Held-to-maturity investments U.S. treasury securities $ 13,179 $ 21 $ (15) $ 13,185 Certificates of deposit 12,298 — — 12,298 $ 25,477 $ 21 $ (15) $ 25,483
Investments Classified by Contractual Maturity Date [Table Text Block]	Maturities of investments classified as available-for-sale and held-to-maturity were as follows (in thousands): As of March 31, 2024 Amortized Fair Available-for-sale: Due under one year $ 4,084 $ 4,050 Due after one year through five years 87,440 87,388 $ 91,524 $ 91,438 Available-for-sale collateralized: Mortgage-backed securities and collateralized mortgage obligations $ 10,905 $ 10,837 Other asset-backed securities 13,571 13,551 $ 24,476 $ 24,388 Held-to-maturity: Due under one year $ 24,917 $ 24,911 Due after one year through five years 998 998 $ 25,915 $ 25,909

Investments, All Other Investme

Investments, All Other Investments (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Debt Securities, Available-for-Sale, Allowance for Credit Loss	rollforward of the allowance for credit losses for this investment. Balance as of January 1, 2023 $ — (Addition to) allowance for credit losses — Balance as of March 31, 2023 $ — Balance as of January 1, 2024 $ (1,674) (Addition to) allowance for credit losses — Balance as of March 31, 2024 $ (1,674)

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of March 31, 2024 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 81,906 $ 81,906 $ — $ — Fixed maturities: Mortgage-backed securities and collateralized mortgage obligations 10,837 — 10,837 — Other asset-backed securities 13,551 — 13,551 — Corporate bonds 36,144 — 36,144 — Foreign deposits 12,009 12,009 — — U.S. Treasury securities 43,285 — 43,285 — Preferred stock investment 5,326 — — 5,326 Total $ 203,058 $ 93,915 $ 103,817 $ 5,326 As of December 31, 2023 Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 67,360 $ 67,360 $ — $ — Fixed maturities: Mortgage-backed securities and collateralized mortgage obligations 10,454 — 10,454 — Other asset-backed securities 12,436 — 12,436 — Corporate bonds 36,613 — 36,613 — Foreign deposits 11,869 11,869 — — U.S. Treasury securities 44,687 — 44,687 — Preferred stock investment 5,326 — — 5,326 Total $ 188,745 $ 79,229 $ 104,190 $ 5,326

Claims Reserve (Tables)

Claims Reserve (Tables)	3 Months Ended
	Mar. 31, 2024
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Short-duration Insurance Contracts, Claims Development [Table Text Block]	In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence. Subscription As of March 31, 2024 Year of Occurrence 2022 and prior $ 698 2023 7,027 2024 22,291 $ 30,016 Other Business As of March 31, 2024 Year of Occurrence 2022 and prior $ 576 2023 5,867 2024 25,816 $ 32,259
Subscription business [Member]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]	Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Three Months Ended March 31, Subscription 2024 2023 Reserve at beginning of year $ 31,549 $ 21,543 Veterinary invoices during the period related to: Current year 151,793 127,343 Prior years 563 1,645 Total veterinary invoice expense 152,356 128,988 Amounts paid during the period related to: Current year 128,639 108,483 Prior years 24,386 17,529 Total paid 153,025 126,012 Non-cash expenses 864 877 Reserve at end of period $ 30,016 $ 23,642
Other Segments [Member]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]	Summarized below are the changes in total liability for the Company's other business segment (in thousands): Three Months Ended March 31, Other Business 2024 2023 Reserve at beginning of year $ 31,690 $ 22,191 Veterinary invoices during the period related to: Current year 80,876 63,948 Prior years 337 1,200 Total veterinary invoice expense 81,213 65,148 Amounts paid during the period related to: Current year 55,059 44,564 Prior years 25,585 18,122 Total paid 80,644 62,686 Non-cash expenses — — Reserve at end of period $ 32,259 $ 24,653

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	Future principal payments on outstanding borrowings as of March 31, 2024 are as follows (in thousands): Year Ending December 31, March 31, 2024 2024 $ 1,012 2025 1,350 2026 1,350 2027 72,113 2028 57,125 Thereafter — Total $ 132,950

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense includes stock options and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in each category of the consolidated statements of operations was as follows (in thousands): Three Months Ended March 31, 2024 2023 Veterinary invoice expense $ 924 $ 853 Other cost of revenue 466 465 Technology and development 1,254 708 General and administrative 3,449 8,219 New pet acquisition expense 2,059 2,086 Total expensed stock-based compensation 8,152 12,331 Capitalized stock-based compensation 206 628 Total stock-based compensation $ 8,358 $ 12,959
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 408,970 $ 14.09 $ 6,715 Granted — — — Exercised (22,658) 16.41 338 Forfeited — — Outstanding as of March 31, 2024 386,312 13.95 5,275 Exercisable as of March 31, 2024 386,312 $ 13.95 $ 5,275
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Restricted Stock Awards and Restricted Stock Units A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2023 714,382 $ 66.64 Granted 761,553 26.92 Vested (200,289) 69.84 Forfeited (12,852) 56.94 Unvested shares as of March 31, 2024 1,262,794 $ 42.28

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	A summary of the components of accumulated other comprehensive income (loss) is as follows (in thousands): For the three months ended March 31, 2024 Foreign Currency Translation Net Unrealized Gain (Loss) on Available-for-Sale Securities Total Balance as of January 1, 2024 $ (76) $ 479 $ 403 Other comprehensive income (loss) (1,332) (652) (1,984) Balance as of March 31, 2024 $ (1,408) $ (173) $ (1,581) For the three months ended March 31, 2023 Foreign Currency Translation Net Unrealized Gain (Loss) on Available-for-Sale Securities Total Balance as of January 1, 2023 $ (2,788) $ (3,513) $ (6,301) Other comprehensive income (loss) 1,555 491 2,046 Balance as of March 31, 2023 $ (1,233) $ (3,022) $ (4,255)

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Revenue and Gross Profit from Segments [Table Text Block]	Operating income (loss) of the Company’s segments were as follows (in thousands): Three Months Ended March 31, 2024 2023 Subscription business: Revenue $ 201,134 $ 165,210 Veterinary invoice expense 152,356 128,988 Other cost of revenue 19,776 17,103 Technology and development 4,573 3,158 General and administrative 9,641 11,073 New pet acquisition expense 16,826 21,591 Depreciation and amortization 2,487 2,064 Subscription business operating loss (4,525) (18,767) Other business: Revenue 104,987 91,119 Veterinary invoice expense 81,213 65,149 Other cost of revenue 16,549 18,743 Technology and development 2,387 1,742 General and administrative 5,032 9,944 New pet acquisition expense 17 51 Depreciation and amortization 1,298 1,138 Other business operating loss (1,509) (5,648) Loss from investment in joint venture (103) (71) Operating loss (6,137) (24,486) Interest expense 3,596 2,387 Other income, net (2,843) (1,902) Loss before income taxes $ (6,890) $ (24,971)
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended March 31, 2024 2023 United States $ 255,974 $ 216,925 Canada and other 50,147 39,404 Total revenue $ 306,121 $ 256,329

Net Loss per Share (Details) Sc

Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	386,312	615,913
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,262,794	813,718

Investment Securities (Details)

Investment Securities (Details) - Investment Schedule - AFS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2023
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	$ 91,438,000
Debt Securities, Available-for-Sale, Unrealized Loss Position	500,000			$ 300,000
Proceeds from Sale of Debt Securities, Available-for-Sale	15,100,000	$ 24,000,000
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	4,084,000
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	87,440,000
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Amortized Cost	91,524,000
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	4,050,000
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	87,388,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer	24,900,000			18,900,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months	39,400,000			25,900,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	300,000			200,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	200,000			100,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	300,000			200,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	200,000			100,000
Other Long-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0			0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	12,009,000			11,869,000
Debt Securities, Available-for-Sale, Amortized Cost	12,009,000			11,869,000
Debt Securities, Available-for-Sale, Unrealized Gain	0		$ 0
Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	2,000			21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(8,000)			(15,000)
Debt Securities, Held-to-maturity, Fair Value	24,911,000			25,483,000
Debt Securities, Available-for-Sale, Unrealized Gain	324,000		794,000
Debt Securities, Held-to-Maturity, Amortized Cost, before Other-than-temporary Impairment	24,917,000			25,477,000
Collateralized Mortgage-Backed Securities
Schedule of Investments [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	10,905,000
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	13,571,000
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Amortized Cost	24,476,000
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	10,837,000
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	13,551,000
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	24,388,000
Collateralized Mortgage-Backed Securities | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(97,000)			(75,000)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	10,837,000			10,454,000
Debt Securities, Available-for-Sale, Amortized Cost	10,905,000			10,460,000
Debt Securities, Available-for-Sale, Unrealized Gain	29,000		69,000
Asset-Backed Securities | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(61,000)			(53,000)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	13,551,000			12,436,000
Debt Securities, Available-for-Sale, Amortized Cost	13,571,000			12,422,000
Debt Securities, Available-for-Sale, Unrealized Gain	41,000		67,000
Corporate Bond Securities | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(132,000)			(123,000)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	36,144,000			36,613,000
Debt Securities, Available-for-Sale, Amortized Cost	36,099,000			36,404,000
Debt Securities, Available-for-Sale, Unrealized Gain	177,000		332,000
US Treasury and Government | Other Long-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	998,000			997,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0			8,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0			0
Debt Securities, Held-to-maturity, Fair Value	998,000			1,005,000
US Treasury and Government | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(208,000)			(64,000)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	43,285,000			44,687,000
Debt Securities, Available-for-Sale, Amortized Cost	43,416,000			44,425,000
Debt Securities, Available-for-Sale, Unrealized Gain	77,000		326,000
Total Short-Term Available-for-Sale [Domain] | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(498,000)			(315,000)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	103,817,000			104,190,000
Debt Securities, Available-for-Sale, Amortized Cost	103,991,000			103,711,000
Deposits [Member] | Other Long-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0			0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	12,009,000			11,869,000
Debt Securities, Available-for-Sale, Amortized Cost	12,009,000			11,869,000
Debt Securities, Available-for-Sale, Unrealized Gain	0		$ 0
Total Long-Term Held-to-Maturity | Other Long-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0			8,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0			0
Debt Securities, Held-to-maturity, Fair Value	998,000			1,005,000
Debt Securities, Held-to-Maturity, Amortized Cost, before Other-than-temporary Impairment	998,000			997,000
US Treasury Securities [Member] | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity	12,929,000			13,179,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	2,000			21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(8,000)			(15,000)
Debt Securities, Held-to-maturity, Fair Value	12,923,000			13,185,000
Certificates of Deposit [Member] | Short-Term Investments
Schedule of Investments [Line Items]
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0			0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0			0
Debt Securities, Held-to-maturity, Fair Value	11,988,000			12,298,000
Debt Securities, Held-to-Maturity, Amortized Cost, before Other-than-temporary Impairment	$ 11,988,000			$ 12,298,000

Investment Securities (Detail_2

Investment Securities (Details) - Investment Schedule - HTM - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One	$ 24,917,000
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five	998,000
Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date	25,915,000
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	24,911,000
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	998,000
Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value	25,909,000
Short-Term Investments
Schedule of Held-to-Maturity Securities [Line Items]
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	2,000	$ 21,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	8,000	15,000
Debt Securities, Held-to-maturity, Fair Value	24,911,000	25,483,000
US Treasury and Government | Other Long-Term Investments
Schedule of Held-to-Maturity Securities [Line Items]
Debt Securities, Held-to-maturity	998,000	997,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0	8,000
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	$ 998,000	$ 1,005,000

Other Investments (Details)

Other Investments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Investments, All Other Investments [Abstract]
Purchase of Equity Interest					$ 7,000,000
Financing Receivable, Revolving	$ 7,000,000
Financing Receivable, after Allowance for Credit Loss	3,300,000		$ 4,000,000
Services performed for Variable Interest Entity	100,000	$ 200,000
Financing Receivable, Revolving, Annual Increase	2,000,000
Preferred Stock
Debt Securities, Available-for-Sale, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Allowance for Credit Loss	(1,674,000)	0	$ (1,674,000)	$ 0
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded	$ 0	$ 0

Fair Value (Details) - Investme

Fair Value (Details) - Investments Schedule - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	$ 91,438,000
Noncontrolling Interest in Variable Interest Entity	5,326,000		$ 5,326,000
Assets, Fair Value Disclosure	203,058,000		188,745,000
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(652,000)	$ 491,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0		0
Assets, Fair Value Disclosure	93,915,000		79,229,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0		0
Assets, Fair Value Disclosure	103,817,000		104,190,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	5,326,000	$ 4,115,000	5,326,000	$ 4,115,000
Assets, Fair Value Disclosure	5,326,000		5,326,000
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	81,906,000		67,360,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	81,906,000		67,360,000
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0		0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0		0
Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	12,009,000		11,869,000
Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	12,009,000		11,869,000
Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0		0
Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0		0
Collateralized Mortgage-Backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	10,837,000		10,454,000
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	10,837,000		10,454,000
Collateralized Mortgage-Backed Securities | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Asset-Backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	13,551,000		12,436,000
Asset-Backed Securities | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Asset-Backed Securities | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	13,551,000		12,436,000
Asset-Backed Securities | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Total Corporate Bond Securities Member LT and ST [Domain]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	36,144,000		36,613,000
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	36,144,000		36,613,000
Total Corporate Bond Securities Member LT and ST [Domain] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Total US Treasury LT and ST Member [Domain]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	43,285,000		44,687,000
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0		0
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	43,285,000		44,687,000
Total US Treasury LT and ST Member [Domain] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	$ 0		$ 0

Fair Value (Details) - Narrativ

Fair Value (Details) - Narrative - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Noncontrolling Interest in Variable Interest Entity	$ 5,326,000		$ 5,326,000
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)	0	$ 0
Notes Receivable, Fair Value Disclosure	6,100,000		6,800,000
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	5,326,000		5,326,000
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value Disclosures [Abstract]
Noncontrolling Interest in Variable Interest Entity	5,326,000	4,115,000	5,326,000	$ 4,115,000
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	$ 5,326,000	$ 4,115,000	$ 5,326,000	$ 4,115,000

Claims Reserve (Details) - Rese

Claims Reserve (Details) - Reserve Rollforward - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Subscription business [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	$ 31,549	$ 21,543
Current Year Claims and Claims Adjustment Expense	151,793	127,343
Prior Year Claims and Claims Adjustment Expense	563	1,645
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	152,356	128,988
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year	128,639	108,483
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years	24,386	17,529
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	153,025	126,012
Claims expense non-cash	864	877
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	30,016	23,642
Other Segments [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	31,690	22,191
Current Year Claims and Claims Adjustment Expense	80,876	63,948
Prior Year Claims and Claims Adjustment Expense	337	1,200
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	81,213	65,148
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year	55,059	44,564
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years	25,585	18,122
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	80,644	62,686
Claims expense non-cash	0	0
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	$ 32,259	$ 24,653

Claims Reserve (Details) - Narr

Claims Reserve (Details) - Narrative - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Subscription business [Member]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	$ 31,549	$ 21,543
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	30,016	23,642
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	152,356	128,988
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	153,025	126,012
Prior Year Claims and Claims Adjustment Expense	563	1,645
Other Segments [Member]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	31,690	22,191
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	32,259	24,653
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	81,213	65,148
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	80,644	62,686
Prior Year Claims and Claims Adjustment Expense	$ 337	$ 1,200

Claims Reserve (Details) - Re_2

Claims Reserve (Details) - Reserve by Year of Occurrence $ in Thousands	Mar. 31, 2024 USD ($)
Subscription business [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 30,016
Other Segments [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	32,259
Short-Duration Insurance Contract, Accident Year 2020 [Member] | Subscription business [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	698
Short-Duration Insurance Contract, Accident Year 2020 [Member] | Other Segments [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	576
Short-Duration Insurance Contract, Accident Year 2021 [Member] | Subscription business [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	7,027
Short-Duration Insurance Contract, Accident Year 2021 [Member] | Other Segments [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	5,867
Short-duration Insurance Contracts, Accident Year 2022 [Member] | Subscription business [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	22,291
Short-duration Insurance Contracts, Accident Year 2022 [Member] | Other Segments [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 25,816

Debt (Details) - Narrative

Debt (Details) - Narrative - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 21, 2023	Feb. 16, 2023	Dec. 29, 2022
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date	Mar. 25, 2022
Line of Credit Facility, Maximum Borrowing Capacity	$ 150,000
Debt Instrument, Interest Rate, Stated Percentage	10.46%
Debt Issuance Costs, Gross	$ 5,900
Line of Credit Facility, Expiration Date	Mar. 25, 2027
Line of Credit Facility, Periodic Payment, Principal Percentage	0.25%
Line of Credit Facility, Frequency of Payments	quarterly
Delayed Draw Term Loan
Line of Credit Facility [Line Items]
Long-term Debt	$ 75,000		$ 25,000	$ 35,000	$ 15,000
Initial Loan
Line of Credit Facility [Line Items]
Long-term Debt		$ 60,000
Unfunded Loan Commitment [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 75,000
Line of Credit, Date of Last Availability	Sep. 25, 2023
Line of Credit Facility, Expiration Date	Mar. 25, 2028
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 15,000
Line of Credit, Date of Last Availability	Mar. 25, 2027
Line of Credit Facility, Expiration Date	Mar. 25, 2027

Debt (Details) - Schedule of Ma

Debt (Details) - Schedule of Maturities $ in Thousands	Mar. 31, 2024 USD ($)
Debt Disclosure [Abstract]
Long-Term Debt, Maturity, Year One	$ 1,012
Long-Term Debt, Maturity, Year Two	1,350
Long-Term Debt, Maturity, Year Three	1,350
Long-Term Debt, Maturity, Year Four	72,113
Long-Term Debt, Maturity, Year Five	57,125
Long-Term Debt, Maturity, after Year Five	0
Long-term Line of Credit, Total	$ 132,950

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Expense Category - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 8,152	$ 12,331
Share-based Compensation Arrangement by Share-based Payment Award, Capitalized Cost	206	628
Share-based Payment Arrangement, Expensed and Capitalized, Amount	8,358	12,959
Claims Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	924	853
Other Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	466	465
Technology and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	1,254	708
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	3,449	8,219
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 2,059	$ 2,086

Share-based Compensation (Detai

Share-based Compensation (Details) - Narrative - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Accelerated Cost	$ 4,800,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1,262,794	714,382
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 56,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 4 months 24 days
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	2 years 4 months 24 days

Stock-based Compensation (Det_2

Stock-based Compensation (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	386,312	408,970
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(22,658)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	386,312
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 13.95	$ 14.09
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	16.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 13.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 5,275	$ 6,715
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	338
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 5,275

Stock-based Compensation (Det_3

Stock-based Compensation (Details) - Restricted Stock Units - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1,262,794	714,382
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	761,553
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(200,289)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(12,852)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 42.28	$ 66.64
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	26.92
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	69.84
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 56.94

Stockholders' Equity (Details)

Stockholders' Equity (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Equity, Attributable to Parent [Abstract]
Common Stock, Shares Authorized	100,000,000		100,000,000
Common Stock, Shares, Outstanding	42,004,619		41,858,866
Preferred Stock, Shares Authorized	10,000,000		10,000,000
Treasury Stock, Shares, Acquired	0	0

Comprehensive Income (Loss) (De

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent, Beginning Balance	$ 303,722	$ 305,297
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(1,332)	1,555
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(652)	491
Other Comprehensive Income (Loss), Net of Tax	(1,984)	2,046
Stockholders' Equity Attributable to Parent, Ending Balance	303,371	294,809
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent, Beginning Balance	(76)	(2,788)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(1,332)	1,555
Stockholders' Equity Attributable to Parent, Ending Balance	(1,408)	(1,233)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent, Beginning Balance	479	(3,513)
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(652)	491
Stockholders' Equity Attributable to Parent, Ending Balance	(173)	(3,022)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity Attributable to Parent, Beginning Balance	403	(6,301)
Other Comprehensive Income (Loss), Net of Tax	(1,984)	2,046
Stockholders' Equity Attributable to Parent, Ending Balance	$ (1,581)	$ (4,255)

Segments (Details) - Business S

Segments (Details) - Business Segments - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 306,121	$ 256,329
Claims Expense	233,569	194,137
Other Cost of Services Sold	36,325	35,846
Technology and Development Expense	6,960	4,900
General and Administrative Expense	14,673	21,017
Selling and Marketing Expense	16,843	21,642
Depreciation, Depletion and Amortization	3,785	3,202
Income (Loss) from Equity Method Investments	(103)	(71)
Operating Income (Loss), Total	(6,137)	(24,486)
Interest Expense	3,596	2,387
Other Nonoperating Income (Expense)	(2,843)	(1,902)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(6,890)	(24,971)
Subscription business [Member]
Segment Reporting Information [Line Items]
Revenues	201,134	165,210
Claims Expense	152,356	128,988
Other Cost of Services Sold	19,776	17,103
Technology and Development Expense	4,573	3,158
General and Administrative Expense	9,641	11,073
Selling and Marketing Expense	16,826	21,591
Depreciation, Depletion and Amortization	2,487	2,064
Operating Income (Loss), Total	(4,525)	(18,767)
Other Segments [Member]
Segment Reporting Information [Line Items]
Revenues	104,987	91,119
Claims Expense	81,213	65,149
Other Cost of Services Sold	16,549	18,743
Technology and Development Expense	2,387	1,742
General and Administrative Expense	5,032	9,944
Selling and Marketing Expense	17	51
Depreciation, Depletion and Amortization	1,298	1,138
Operating Income (Loss), Total	$ (1,509)	$ (5,648)

Segments (Details) - Revenue by

Segments (Details) - Revenue by Geography - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 306,121	$ 256,329
United States
Segment Reporting Information [Line Items]
Revenues	255,974	216,925
Canada and other
Segment Reporting Information [Line Items]
Revenues	$ 50,147	$ 39,404